European Commission Votes in Favor on Nicotinamide Riboside Chloride as a Novel Food
November 20 2019 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC) today announced that European Member
States have voted in favor of listing Nicotinamide Riboside
Chloride (NR) as a novel food ingredient at a daily serving of
300mg for the healthy adult population.
This approval follows a positive opinion issued by
the European Food Safety Authority (EFSA) in August 2019.
“We are pleased to be extending our global
footprint into Europe,” says ChromaDex CEO Rob Fried. “We are
committed to offering Tru Niagen to health-conscious people
worldwide.”
“The decision by the European Commission is a
meaningful occasion not only for ChromaDex but also for researchers
around the world studying nicotinamide riboside,” says Professor
Sir John Walker, Nobel Laureate and Emeritus Director, MRC
Mitochondrial Biology Unit in the University of Cambridge, England,
and member of the ChromaDex Scientific Advisory Board (SAB).
“ChromaDex has been at the forefront of both clinical and
preclinical research behind NR and NAD.”
Dr. Charles Brenner, the Roy J. Carver Chair and
Head of Biochemistry at the University of Iowa and ChromaDex Chief
Scientific Advisor, will present the science behind nicotinamide
riboside (NR) today at the Food Matters Summit taking place in
London.
“This is a celebratory occasion for researchers
around the globe who understand the great potential of nicotinamide
riboside and its important role in raising NAD levels,” says Dr.
Brenner who discovered NR as a vitamin and NAD-booster in 2004.
Tru Niagen is a breakthrough supplement clinically
proven to increase your NAD (nicotinamide adenine dinucleotide)
levels which stimulate cellular energy production and support
cellular repair. Decreased NAD levels have been associated with
many age-related declines in overall health. Nicotinamide riboside
chloride (NR) has been the subject of rigorous preclinical safety
and toxicology studies laying the groundwork for the published
clinical studies that demonstrate safety and efficacy.
To date, ChromaDex has invested millions of dollars
in safety and human clinical trials on its patent-protected NR
(commercially known as Niagen) and has entered research agreements
with more than 170 leading research institutions, including
Dartmouth, the National Institutes of Health, University of Iowa,
and the Scripps Research Institute.
For additional information on the science
supporting Niagen visit www.chromadex.com.
About TRU NIAGEN®:TRU NIAGEN® is a
branded dietary supplement brought to market by key nicotinamide
riboside chloride innovator and patent holder, ChromaDex. NIAGEN®
nicotinamide riboside chloride (NR), also supplied by ChromaDex, is
the sole active ingredient in TRU NIAGEN®. Multiple clinical trials
demonstrate NIAGEN® is proven to boost NAD (nicotinamide adenine
dinucleotide) levels, which decline with age. Only NIAGEN® has
twice been successfully reviewed under FDA's new dietary ingredient
(“NDI”) notification program, and has also been successfully
notified to the FDA as generally recognized as safe (“GRAS”).
About ChromaDex:ChromaDex Corp. is
a science-based integrated nutraceutical company devoted to
improving the way people age. ChromaDex scientists partner with
leading universities and research institutions worldwide to uncover
the full potential of NAD and identify and develop novel,
science-based ingredients. Its flagship ingredient, NIAGEN®
nicotinamide riboside chloride, sold directly to consumers as TRU
NIAGEN®, is backed with clinical and scientific research, as well
as extensive IP protection. TRU NIAGEN® is helping the world AGE
BETTER®. ChromaDex maintains a website at www.chromadex.com to
which ChromaDex regularly posts copies of its press releases as
well as additional and financial information about the Company.
Forward-Looking Statements:This
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities and Exchange Act of 1934, as amended.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2018, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
ChromaDex Media Contact:Alex
Worsham, Senior Director of Global Corporate
Communications310-388-6706 ext. 689alexw@chromadex.com
ChromaDex Investor Relations
Contact:Brianna Gerber, Vice President of FP&A and
Investor Relations949-419-0288 ext. 127briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Sep 2024 to Oct 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Oct 2023 to Oct 2024